RhoVac® seeks a partnership among larger oncology focused pharmaceutical companies, companies that have the capability and the financial strength to run a broad-based phase III program and that, after regulatory approval, are able to successfully launch the product globally.
We will consider both licensing and acquisition/divestment options after the phase IIB study results are at hand in 2021, and we could consider an option deal prior to that.
Tel. +46 708 60 47 38
November 11-13, 2019
BIO Europe, Hamburg